Gastrointestinal stromal tumors (GISTs) form a rare and distinct group of cancers in the digestive tract. Adenocarcinomas usually grow from the epithelial lining of the stomach or colon, but GISTs arise from the interstitial cells of Cajal (ICCs) or their precursors. These ICCs act as the gut’s pacemaker cells and control peristalsis. This difference in origin separates GISTs from other gastrointestinal cancers.

What are GISTs?

Gastrointestinal stromal tumors (GISTs) are rare tumors that start in the digestive tract, mainly in the stomach or small intestine. They originate from the interstitial cells of Cajal (ICCs), the gut’s pacemaker cells.

How are they different from other GI cancers?

Most GI cancers (like stomach or colon adenocarcinomas) develop from the epithelial lining. GISTs form from ICCs instead, making them biologically different, diagnosed differently, and treated with targeted therapies rather than standard chemotherapy.

Symptoms and early diagnosis methods

GISTs often appear in the stomach and small intestine, but they can develop anywhere in the GI tract. The symptoms may be abdominal pain, bleeding or dark stools, or difficulty swallowing, all depending on the tumor’s location and size. For diagnosis, endoscopic ultrasound and CT scans are the main imaging tools. A definitive diagnosis is found by a biopsy and immunohistochemistry. A positive report for the KIT protein confirms GISTs, by the molecular subtype, and requires further treatment.

How have KIT mutations transformed GIST treatment?

The identification of KIT mutations changed GIST treatment; before then, GISTs were resistant to chemotherapy and radiation. Targeted therapies like imatinib treatment, where a small molecular inhibitor of the KIT and PDGFRA tyrosine kinases changes GIST to a manageable chronic condition rather than a quick fatal disease for many patients. Imatinib blocks the mutated and continuously active receptors selectively and stops tumor growth. Patients developing a resistance to imatinib are given secondary treatment of sunitinib and regorafenib, targeting multiple kinase pathways. Molecular targeted agents are also different from other GI cancers, as they rely on cytotoxic chemotherapies.

Survival outcomes and long-term care

Targeted therapy has significantly improved survival for people with GIST, especially in advanced or metastatic cases. Treatment usually involves surgery first, followed by adjuvant tyrosine kinase inhibitor (TKI) therapy to lower the risk of relapse. Long-term management requires regular monitoring and strict treatment adherence, often for several years. Outcomes depend on factors like tumor size, location, and mitotic rate, but survival has improved greatly since the shift to targeted treatments.

GISTs differ from other GI cancers because they arise from interstitial cells of Cajal and are driven by mutations in KIT or PDGFRA. These molecular changes make GISTs highly responsive to TKI therapy. Current research focuses on overcoming resistance and developing more personalized treatment options, further improving long-term outcomes.